BioNTech SE (BNTX)
112.82
-3.75
(-3.22%)
USD |
NASDAQ |
Aug 24, 16:00
113.17
+0.35
(+0.31%)
After-Hours: 20:00
BioNTech Price to Book Value : 1.396 for Aug. 24, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 1.442 |
| August 20, 2026 | 1.372 |
| August 19, 2026 | 1.400 |
| August 18, 2026 | 1.148 |
| August 17, 2026 | 1.133 |
| August 14, 2026 | 1.152 |
| August 13, 2026 | 1.140 |
| August 12, 2026 | 1.148 |
| August 11, 2026 | 1.148 |
| August 10, 2026 | 1.148 |
| August 07, 2026 | 1.159 |
| August 06, 2026 | 1.128 |
| August 05, 2026 | 1.141 |
| August 04, 2026 | 1.130 |
| August 03, 2026 | 1.141 |
| July 31, 2026 | 1.121 |
| July 30, 2026 | 1.149 |
| July 29, 2026 | 1.150 |
| July 28, 2026 | 1.144 |
| July 27, 2026 | 1.127 |
| July 24, 2026 | 1.105 |
| July 23, 2026 | 1.139 |
| July 22, 2026 | 1.136 |
| July 21, 2026 | 1.142 |
| July 20, 2026 | 1.140 |
| Date | Value |
|---|---|
| July 17, 2026 | 1.132 |
| July 16, 2026 | 1.133 |
| July 15, 2026 | 1.138 |
| July 14, 2026 | 1.118 |
| July 13, 2026 | 1.114 |
| July 10, 2026 | 1.132 |
| July 09, 2026 | 1.150 |
| July 08, 2026 | 1.157 |
| July 07, 2026 | 1.167 |
| July 06, 2026 | 1.162 |
| July 02, 2026 | 1.207 |
| July 01, 2026 | 1.162 |
| June 30, 2026 | 1.151 |
| June 29, 2026 | 1.106 |
| June 26, 2026 | 1.071 |
| June 25, 2026 | 1.056 |
| June 24, 2026 | 1.059 |
| June 23, 2026 | 1.064 |
| June 22, 2026 | 1.059 |
| June 18, 2026 | 1.067 |
| June 17, 2026 | 1.082 |
| June 16, 2026 | 1.051 |
| June 15, 2026 | 1.066 |
| June 12, 2026 | 1.063 |
| June 11, 2026 | 1.051 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Moderna, Inc. | 8.192 |
| Biodexa Pharmaceuticals Plc | -- |
| Mereo BioPharma Group Plc | 1.621 |
| NuCana Plc | 39.20 |
| MediGene AG | -- |
Price to Book Value Related Metrics
| PS Ratio | 9.028 |
| PEG Ratio | -0.0369 |
| Price to Free Cash Flow | 65.78 |
| Price | 112.82 |
| Earnings Yield | -6.96% |
| Market Cap | 28.34B |
| PEGY Ratio | -0.0369 |